United States of America
Prospective observational study
Medical records
1376
consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation to the emergency department
Of the 1376 patients, 811 (58.9%) received hydroxychloroquine (median duration of treatment, 5 days) and 565 (41.1%) did not.
Median
23 Day
COVID-19 (severe/fatal)
346
The primary end point was a composite of intubation or death in a time-to-event analysis. Overall, 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently died, and 166 died without intubation).
Treatment
Treatment for COVID-19
Hydroxychloroquine treatment
Not received
Treated with hydroxychloroquine
Hazard ratio
0.970 (0.740-1.280)
No
Yes
hazard ratio from a multivariable Cox proportional-hazards model with the same strata and covariates, with additional adjustment for the propensity score. The analysis included all the patients.
none
Good